JP2022523507A5 - - Google Patents

Info

Publication number
JP2022523507A5
JP2022523507A5 JP2021544406A JP2021544406A JP2022523507A5 JP 2022523507 A5 JP2022523507 A5 JP 2022523507A5 JP 2021544406 A JP2021544406 A JP 2021544406A JP 2021544406 A JP2021544406 A JP 2021544406A JP 2022523507 A5 JP2022523507 A5 JP 2022523507A5
Authority
JP
Japan
Prior art keywords
binding molecule
sequence
amino acid
specific binding
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544406A
Other languages
English (en)
Japanese (ja)
Other versions
JP7530904B2 (ja
JP2022523507A (ja
Filing date
Publication date
Priority claimed from GBGB1901305.1A external-priority patent/GB201901305D0/en
Application filed filed Critical
Publication of JP2022523507A publication Critical patent/JP2022523507A/ja
Publication of JP2022523507A5 publication Critical patent/JP2022523507A5/ja
Application granted granted Critical
Publication of JP7530904B2 publication Critical patent/JP7530904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544406A 2019-01-30 2020-01-30 特異的結合性分子 Active JP7530904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1901305.1 2019-01-30
GBGB1901305.1A GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules
PCT/EP2020/052315 WO2020157210A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules

Publications (3)

Publication Number Publication Date
JP2022523507A JP2022523507A (ja) 2022-04-25
JP2022523507A5 true JP2022523507A5 (cg-RX-API-DMAC7.html) 2023-03-10
JP7530904B2 JP7530904B2 (ja) 2024-08-08

Family

ID=65997940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544406A Active JP7530904B2 (ja) 2019-01-30 2020-01-30 特異的結合性分子

Country Status (12)

Country Link
US (1) US12590152B2 (cg-RX-API-DMAC7.html)
EP (1) EP3917959A1 (cg-RX-API-DMAC7.html)
JP (1) JP7530904B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984612B1 (cg-RX-API-DMAC7.html)
CN (1) CN113728005B (cg-RX-API-DMAC7.html)
AU (1) AU2020215776A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014963A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127144A1 (cg-RX-API-DMAC7.html)
GB (1) GB201901305D0 (cg-RX-API-DMAC7.html)
IL (1) IL284926B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009275A (cg-RX-API-DMAC7.html)
WO (1) WO2020157210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药(杭州)有限公司 一种接近天然分子的多肽融合分子
JP2025508738A (ja) 2022-02-20 2025-04-10 イムノコア リミテッド Hiv特異的結合分子及びtcr
TW202423994A (zh) 2022-08-18 2024-06-16 英商英美偌科有限公司 多域結合分子
KR20250133715A (ko) 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
IL321809A (en) 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex
TW202519257A (zh) * 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
GB202418912D0 (en) 2024-12-20 2025-02-05 Immunocore Ltd Specific binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36676A (en) 1862-10-14 Improvement in grain-cleaners
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5855530Y2 (ja) 1981-06-15 1983-12-20 松下電工株式会社 照明器具を有する天井
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
BR112015000798A2 (pt) 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
US12103971B2 (en) * 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
WO2024038165A1 (en) * 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
KR20250133715A (ko) * 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
IL321809A (en) * 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex

Similar Documents

Publication Publication Date Title
Wang et al. Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment
JP6490038B2 (ja) 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2021528973A5 (cg-RX-API-DMAC7.html)
JP2022177097A (ja) ヘテロ二量体多重特異性抗体フォーマット
JP2022548043A5 (cg-RX-API-DMAC7.html)
EP2050764A1 (en) Novel polyvalent bispecific antibody format and uses thereof
JP2017529067A (ja) Cd3結合ドメイン
JP2013500703A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
CA3232364A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
HRP20191083T1 (hr) Molekule antitijela za tim-3 i njihove upotrebe
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
TW201803899A (zh) 三特異性和/或三價結合蛋白
US20200181263A1 (en) Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
JP2014158485A5 (cg-RX-API-DMAC7.html)
US11365240B2 (en) Anti-HSA antibodies
JP2023532129A5 (cg-RX-API-DMAC7.html)
JP2025506341A5 (cg-RX-API-DMAC7.html)
JP2022534433A (ja) 抗gal9免疫阻害性結合分子
TW202204424A (zh) 用於人類疾病之治療的cd38抗體
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
JP2025517120A5 (cg-RX-API-DMAC7.html)
KR20240031229A (ko) 알파-시누클레인병증 치료용 항체